{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:59:02Z","timestamp":1784303942414,"version":"3.55.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.diabres.2026.113109","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:43:29Z","timestamp":1768981409000},"page":"113109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pharmacovigilance analysis of the association between SGLT-2 inhibitors and diabetic foot infections using the FAERS database: An observational study"],"prefix":"10.1016","volume":"232","author":[{"given":"Siqi","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113109_b0005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fnut.2020.00109","article-title":"Association between serum 25-OH-Vitamin D and diabetic foot ulcer in patients with type 2 diabetes","volume":"7","author":"Dai","year":"2020","journal-title":"Front Nutr"},{"key":"10.1016\/j.diabres.2026.113109_b0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/nyas.13569","article-title":"Update on management of diabetic foot ulcers","volume":"1411","author":"Everett","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.diabres.2026.113109_b0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12933-021-01276-9","article-title":"SGLT2 inhibitors and lower limb complications: an updated meta\u2010analysis","volume":"20","author":"Lin","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113109_b0020","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.pcd.2021.12.007","article-title":"Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: a meta-analysis","volume":"16","author":"Du","year":"2022","journal-title":"Prim Care Diabet"},{"key":"10.1016\/j.diabres.2026.113109_b0025","article-title":"Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabres.2026.113109_b0030","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s00125-024-06316-z","article-title":"Increased risk of major adverse cardiovascular events in patients with deep and infected diabetes-related foot ulcers","volume":"68","author":"Lan","year":"2025","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2026.113109_b0035","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s12933-024-02527-1","article-title":"Unravelling the cardio-renal-metabolic-foot connection in people with diabetes-related foot ulceration: a narrative review","volume":"23","author":"Lan","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113109_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11226844","article-title":"Cardiovascular\/stroke risk stratification in diabetic foot infection patients using deep learning-based artificial intelligence: an investigative study","volume":"11","author":"Khanna","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.diabres.2026.113109_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117090","article-title":"Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: a mechanistic review","volume":"240","author":"Yaribeygi","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.diabres.2026.113109_b0050","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J Am Soc Nephrol JASN"},{"key":"10.1016\/j.diabres.2026.113109_b0055","unstructured":"Research, C. for D. E. and. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors. FDA (2018)."},{"key":"10.1016\/j.diabres.2026.113109_b0060","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01512-w","article-title":"The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management","volume":"21","author":"Xu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113109_b0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","article-title":"Direct cardiac effects of SGLT2 inhibitors","volume":"21","author":"Chen","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113109_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110766","article-title":"Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry","volume":"202","author":"Paolisso","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2026.113109_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis","volume":"16","author":"Menne","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.diabres.2026.113109_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.766125","article-title":"Safety of SGLT2 Inhibitors: a pharmacovigilance study from 2013 to 2021 based on FAERS","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabres.2026.113109_b0085","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","article-title":"Sodium\u2013glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus","volume":"16","author":"Scheen","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabres.2026.113109_b0090","article-title":"Sodium-Glucose Cotransporter-2 (SGLT2) inhibitor therapy for the primary and secondary prevention of heart failure in patients with and without type 2 diabetes mellitus: a systematic review","volume":"15","author":"Wahinya","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.diabres.2026.113109_b0095","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-021-01213-w","article-title":"Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113109_b0100","article-title":"SGLT2 inhibitors for diabetes are linked to increased risk of lower limb amputation","volume":"363","author":"Kmietowicz","year":"2018","journal-title":"Br Med J"},{"key":"10.1016\/j.diabres.2026.113109_b0105","article-title":"Amputation risk in type II diabetes mellitus patients treated with SGLT-2 inhibitors: a systematic literature review of randomized clinical trials","volume":"74","author":"Hoda","year":"2024","journal-title":"Drug Res"},{"key":"10.1016\/j.diabres.2026.113109_b0110","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"The BMJ"},{"key":"10.1016\/j.diabres.2026.113109_b0115","doi-asserted-by":"crossref","DOI":"10.1177\/20420986231178126","article-title":"Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients","volume":"14","author":"Lu","year":"2023","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.diabres.2026.113109_b0120","first-page":"5376","article-title":"A meta\u2010analysis of randomized controlled studies examining the effects of sodium\u2010glucose co\u2010transporter\u20102 inhibitors on peripheral artery disease and risk of amputations","volume":"26","author":"Geng","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2026.113109_b0125","first-page":"46","article-title":"SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic","volume":"13","author":"Sung","year":"2018","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.diabres.2026.113109_b0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.diabres.2026.113109_b0135","unstructured":"OpenVigil Pharmacovigilance Search Engines. https:\/\/openvigil.sourceforge.net\/."},{"key":"10.1016\/j.diabres.2026.113109_b0140","doi-asserted-by":"crossref","first-page":"10359","DOI":"10.1038\/s41598-025-95021-x","article-title":"Risk assessment of the top 50 drugs associated with drug-induced orthostatic hypotension: a disproportionality analysis of the FAERS and JADER databases","volume":"15","author":"Ren","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabres.2026.113109_b0145","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.ijmedinf.2009.01.001","article-title":"Influence of the MedDRA hierarchy on pharmacovigilance data mining results","volume":"78","author":"Pearson","year":"2009","journal-title":"Int J Med Inf"},{"key":"10.1016\/j.diabres.2026.113109_b0150","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40264-019-00899-y","article-title":"Investigating overlap in signals from EVDAS, FAERS, and VigiBase\u00ae","volume":"43","author":"Vogel","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.diabres.2026.113109_b0155","unstructured":"Introductory Guide for Standardised MedDRA Queries (SMQs) Version 25.0."},{"key":"10.1016\/j.diabres.2026.113109_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA \u2013 inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.diabres.2026.113109_b0165","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.diabres.2026.113109_b0170","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.diabres.2026.113109_b0175","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.diabres.2026.113109_b0180","doi-asserted-by":"crossref","DOI":"10.2337\/dc17-1551","article-title":"Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113109_b0185","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.119.044775","article-title":"Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58","volume":"142","author":"Bonaca","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2026.113109_b0190","article-title":"Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study","volume":"370","author":"Fralick","year":"2020","journal-title":"The BMJ"},{"key":"10.1016\/j.diabres.2026.113109_b0195","first-page":"1672","article-title":"Sodium\u2010glucose co\u2010transporter\u20102 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: an updated meta\u2010analysis","volume":"23","author":"Giugliano","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2026.113109_b0200","article-title":"SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113109_b0205","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01474-z","article-title":"The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs","volume":"21","author":"Giugliano","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113109_b0210","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1016\/j.jtcvs.2023.08.017","article-title":"Canagliflozin improves coronary microvascular vasodilation and increases absolute blood flow to the myocardium independent of angiogenesis","volume":"166","author":"Banerjee","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.diabres.2026.113109_b0215","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s10557-020-07083-w","article-title":"Novel anti-inflammatory effects of canagliflozin involving hexokinase II in lipopolysaccharide-stimulated human coronary artery endothelial cells","volume":"35","author":"Uthman","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.diabres.2026.113109_b0220","article-title":"Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways","volume":"10","author":"Hasan","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabres.2026.113109_b0225","article-title":"Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females","author":"Doi","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.diabres.2026.113109_b0230","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/ndt\/gfae198","article-title":"Canagliflozin and iron metabolism in the CREDENCE trial","volume":"40","author":"Koshino","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.diabres.2026.113109_b0235","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ekir.2023.11.024","article-title":"Autoantibodies to erythropoietin receptor and clinical outcomes in patients with type 2 diabetes and CKD: a post hoc analysis of CREDENCE trial","volume":"9","author":"Koshino","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.diabres.2026.113109_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(20)30300-4","article-title":"Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial","volume":"8","author":"Oshima","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2026.113109_b0245","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/dia.2019.0212","article-title":"Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease","volume":"21","author":"Maruyama","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.diabres.2026.113109_b0250","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacbts.2018.11.010","article-title":"Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction","volume":"4","author":"Connelly","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.diabres.2026.113109_b0255","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-020-0994-y","article-title":"Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction","volume":"19","author":"Connelly","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113109_b0260","article-title":"Direct cardiac actions of the sodium glucose co\u2010transporter 2 inhibitor empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure\u2010overload heart failure","volume":"10","author":"Li","year":"2021","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"key":"10.1016\/j.diabres.2026.113109_b0265","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/1753-0407.13372","article-title":"Mechanisms of diabetic foot ulceration: a review","volume":"15","author":"Deng","year":"2023","journal-title":"J Diabetes"},{"key":"10.1016\/j.diabres.2026.113109_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112713","article-title":"Molecular immunological mechanisms of impaired wound healing in diabetic foot ulcers (DFU), current therapeutic strategies and future directions","volume":"139","author":"Mohsin","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.diabres.2026.113109_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2023.05.001","article-title":"Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity","author":"Jenkins","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabres.2026.113109_b0280","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s42003-023-05289-w","article-title":"The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy","volume":"6","author":"Ali","year":"2023","journal-title":"Commun Biol"},{"key":"10.1016\/j.diabres.2026.113109_b0285","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5483\/BMBRep.2024-0198","article-title":"mTORC1 and STAT3 signaling are indispensable for in vitro TGF\u03b21-dependent three-dimensional (3D) tendon constructs","volume":"58","author":"Koo","year":"2025","journal-title":"BMB Rep"},{"key":"10.1016\/j.diabres.2026.113109_b0290","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/evj.13184","article-title":"Influence of digital hypothermia on lamellar events related to IL-6\/gp130 signalling in equine sepsis-related laminitis","volume":"52","author":"Dern","year":"2020","journal-title":"Equine Vet J"},{"key":"10.1016\/j.diabres.2026.113109_b0295","article-title":"Empagliflozin restores neutropenia and neutrophil dysfunction in a young patient with severe congenital neutropenia type 4","author":"L\u00e9deczi","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.diabres.2026.113109_b0300","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9944880","article-title":"Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK\/NF-\u03baB, MKK7\/JNK, and JAK2\/STAT1 signalling pathways","volume":"2021","author":"Lee","year":"2021","journal-title":"J Immunol Res"},{"key":"10.1016\/j.diabres.2026.113109_b0305","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymgme.2024.108144","article-title":"Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop","volume":"141","author":"Gr\u00fcnert","year":"2024","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.diabres.2026.113109_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107492","article-title":"The SGLT2 inhibitor empagliflozin negatively regulates IL-17\/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK\/mTOR\/autophagy pathway","volume":"94","author":"Meng","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.diabres.2026.113109_b0315","article-title":"Canagliflozin alleviates atherosclerosis progression through inflammation, oxidative stress, and autophagy in western diet-fed ApoE\u2212\/\u2212 mice","author":"Zuo","year":"2024","journal-title":"Cardiovasc Innov Appl"},{"key":"10.1016\/j.diabres.2026.113109_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101527","article-title":"Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1","volume":"32","author":"Behnammanesh","year":"2020","journal-title":"Redox Biol"},{"key":"10.1016\/j.diabres.2026.113109_b0325","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202403109R","article-title":"Canagliflozin delays aortic valve calcification by enhancing the AMPK\/Nrf2\/HO\u20101 antioxidant signaling pathway in valvular interstitial cells","volume":"39","author":"Zhao","year":"2025","journal-title":"FASEB J"},{"key":"10.1016\/j.diabres.2026.113109_b0330","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-23420-4","article-title":"Canagliflozin inhibits interleukin-1\u03b2-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms","volume":"8","author":"Mancini","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabres.2026.113109_b0335","doi-asserted-by":"crossref","first-page":"10325","DOI":"10.1007\/s11033-023-08855-x","article-title":"Canagliflozin ameliorates high glucose-induced apoptosis in NRK-52E cells via inhibiting oxidative stress and activating AMPK\/mTOR-mediated autophagy","volume":"50","author":"Liu","year":"2023","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.diabres.2026.113109_b0340","doi-asserted-by":"crossref","first-page":"13336","DOI":"10.3390\/ijms222413336","article-title":"Canagliflozin modulates hypoxia-induced metastasis, angiogenesis and glycolysis by decreasing HIF-1\u03b1 protein synthesis via AKT\/mTOR pathway","volume":"22","author":"Luo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabres.2026.113109_b0345","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3390\/jcm12041356","article-title":"The sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin reverses hyperglycemia-induced monocyte and endothelial dysfunction primarily through glucose transport-independent but redox-dependent mechanisms","volume":"12","author":"Semo","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.diabres.2026.113109_b0350","doi-asserted-by":"crossref","DOI":"10.1111\/iwj.14931","article-title":"The incidence of lower extremity amputation and its associated risk factors in patients with diabetic foot ulcers: a meta\u2010analysis","volume":"21","author":"Luo","year":"2024","journal-title":"Int Wound J"},{"key":"10.1016\/j.diabres.2026.113109_b0355","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s00125-019-4839-8","article-title":"Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program","volume":"62","author":"Matthews","year":"2019","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.diabres.2026.113109_b0360","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"CANVAS program collaborative group. canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.diabres.2026.113109_b0365","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1210\/clinem\/dgac596","article-title":"Management of individuals with diabetes at high risk for hypoglycemia: an endocrine society clinical practice guideline","volume":"108","author":"McCall","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.diabres.2026.113109_b0370","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2337\/dc15-2237","article-title":"Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess?","volume":"39","author":"Smith","year":"2016","journal-title":"Diabetes Care"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726000288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726000288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:33:54Z","timestamp":1779111234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726000288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":74,"alternative-id":["S0168822726000288"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113109","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacovigilance analysis of the association between SGLT-2 inhibitors and diabetic foot infections using the FAERS database: An observational study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113109"}}